Regardless, the collective results of these studies point to the possibility that HFD acts through AHR to cause obesity and steatosis, potentially through alteration in production of a metabolite (or metabolites) that acts as an AHR ligand. The gene discussed is AHR; the disease is obesity due to melanocortin 4 receptor deficiency.